Mounjaro and Your Liver: What to Monitor on GLP-1 Therapy
Patient and clinician guide to liver monitoring on Mounjaro (tirzepatide) and other GLP-1 agonists — why elastography matters when weight loss meds also reduce fatty liver.
Mounjaro (tirzepatide) and other GLP-1 / GIP-GLP-1 agonists are now widely prescribed in Australia for type 2 diabetes and weight management. Many patients on these medications also have metabolic-associated fatty liver disease (MAFLD/MASLD) — and the question of how the liver is responding to treatment is increasingly common in primary care.
This article summarises what's worth monitoring, why fibrosis tracking is not the same as monitoring ALT alone, and how non-invasive liver elastography fits into the picture for patients on tirzepatide, semaglutide, or related agents.
Why liver monitoring matters on GLP-1 therapy
GLP-1 receptor agonists drive significant weight loss in many patients, and weight loss above 7–10% is independently associated with reductions in liver fat and inflammation. Tirzepatide trials (SURMOUNT, SURPASS) and semaglutide trials (STEP) have shown meaningful improvements in liver biomarkers alongside weight loss.
But the relationship between weight loss and fibrosis regression is not one-to-one. ALT can normalise while fibrosis persists. Conversely, some patients see lab values improve dramatically while underlying scarring continues to progress more slowly. ALT is necessary but not sufficient.
What to monitor — and how often
For patients on GLP-1 therapy who have established MAFLD or risk factors (type 2 diabetes, BMI >30, metabolic syndrome): a baseline FIB-4 score and, where indicated, baseline liver elastography are reasonable. Repeat FIB-4 every 6–12 months and consider repeat elastography at 12-monthly intervals while on long-term treatment.
Baveno VII guidance suggests that a change of ≥5 kPa between elastography measurements is clinically meaningful in chronic liver disease. This threshold applies whether stiffness is improving or worsening, and it's a useful anchor when discussing results with patients.
What Mounjaro and similar drugs don't do
GLP-1 agonists are not a substitute for liver-specific fibrosis monitoring, especially for patients who already have intermediate or advanced fibrosis at baseline. Improvement on the scales does not mean the scarring is resolved.
Resmetirom (Rezdiffra) — the first FDA-approved MASH-specific therapy — operates on a different mechanism and is the only medication currently licensed in the United States for the histological features of MASH with significant fibrosis. TGA submission in Australia is anticipated; until then, lifestyle and metabolic management remain the foundation.
Practical takeaways
If you're starting GLP-1 therapy and have any liver risk factors, ask your GP about baseline FIB-4 and whether elastography is appropriate. If you're already on therapy, the same baseline plus follow-up cadence applies.
For clinicians: GLP-1 patients are a high-yield cohort for proactive fibrosis screening, and 12-monthly elastography integrates well into routine T2DM and weight management review.
Keep reading